Is Indrapr.Medical overvalued or undervalued?

Oct 28 2025 08:04 AM IST
share
Share Via
As of October 27, 2025, Indrapr.Medical is fairly valued with a PE ratio of 30.83, an EV to EBITDA of 19.37, and a ROE of 28.10%, showing strong performance with a 40.12% return over the past year, but lower than peers like Max Healthcare and Apollo Hospitals.
As of 27 October 2025, Indrapr.Medical's valuation grade has moved from attractive to fair, indicating a shift in market perception. The company is currently fairly valued. Key ratios include a PE ratio of 30.83, an EV to EBITDA of 19.37, and a ROE of 28.10%.

In comparison to its peers, Indrapr.Medical's PE ratio is significantly lower than that of Max Healthcare, which is at 95.77, and Apollo Hospitals, which stands at 71.65. While Indrapr.Medical has shown strong performance with a 1-year return of 40.12% compared to the Sensex's 6.77%, the current valuation suggests it is neither undervalued nor overvalued, aligning with its fair valuation status.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News